NYSE:ADCT ADC Therapeutics Q2 2025 Earnings Report $3.16 +0.29 (+10.10%) Closing price 07/9/2025 03:57 PM EasternExtended Trading$3.20 +0.04 (+1.27%) As of 09:06 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast ADC Therapeutics EPS ResultsActual EPSN/AConsensus EPS -$0.36Beat/MissN/AOne Year Ago EPSN/AADC Therapeutics Revenue ResultsActual RevenueN/AExpected Revenue$17.82 millionBeat/MissN/AYoY Revenue GrowthN/AADC Therapeutics Announcement DetailsQuarterQ2 2025Date8/5/2025TimeBefore Market OpensConference Call DateTuesday, August 5, 2025Conference Call Time8:30AM ETConference Call ResourcesEarnings HistoryCompany Profile ADC Therapeutics Earnings HeadlinesADC Therapeutics Makes Grant to New Employee Under Inducement PlanJuly 1, 2025 | prnewswire.comADCT - ADC Therapeutics SA Financials - MorningstarJune 26, 2025 | morningstar.comMYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what the Department of Justice just admitted in court—claiming cash isn't legally your property. What does that mean? It means Washington thinks they can seize, freeze, or drain your accounts—whenever they want.July 10 at 2:00 AM | Priority Gold (Ad)RBC Capital Sticks to Its Buy Rating for ADC Therapeutics (ADCT)June 22, 2025 | theglobeandmail.comADC Therapeutics price target lowered to $5 at RBC on growth outlookJune 21, 2025 | investing.com - Related Stocks: NYSE:ADCT,June 16, 2025 | gurufocus.comSee More ADC Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like ADC Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ADC Therapeutics and other key companies, straight to your email. Email Address About ADC TherapeuticsADC Therapeutics (NYSE:ADCT) is a clinical-stage biopharmaceutical company focused on the development and commercialization of antibody-drug conjugates (ADCs) to treat hematological malignancies and solid tumors. Utilizing its proprietary pyrrolobenzodiazepine (PBD) cytotoxin platform, the company designs targeted therapies that deliver powerful anti-cancer agents directly to tumor cells while minimizing systemic exposure. ADC Therapeutics oversees all stages of drug development from discovery and preclinical evaluation through clinical trials and regulatory approval. The company’s lead product, loncastuximab tesirine (marketed as Zynlonta), received regulatory approval for the treatment of relapsed or refractory large B-cell lymphoma. Beyond this first-in-class ADC, ADC Therapeutics has multiple additional candidates in its pipeline, including camidanlumab tesirine for Hodgkin lymphoma and several earlier-stage programs targeting solid tumors and other blood cancers. The organization collaborates with academic institutions and industry partners to explore combination therapies, expand indications, and enhance the therapeutic potential of its ADC platform. Founded in 2011 as a spin-out of the UK-based ADC specialist Spirogen, ADC Therapeutics is headquartered in Lausanne, Switzerland, with a major research and development hub in Princeton, New Jersey. The company completed its initial public offering on the New York Stock Exchange in 2018 under the ticker ADCT. Led by an experienced management team with deep expertise in oncology drug development and commercialization, ADC Therapeutics continues to execute its strategic vision of bringing targeted, high-potency cancer therapies to patients worldwide.Written by Jeffrey Neal JohnsonView ADC Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Smith & Wesson Stock Falls on Earnings Miss, Tariff WoesWhat to Expect From the Q2 Earnings Reporting CycleBroadcom Slides on Solid Earnings, AI Outlook Still StrongFive Below Pops on Strong Earnings, But Rally May StallRed Robin's Comeback: Q1 Earnings Spark Investor HopesOllie’s Q1 Earnings: The Good, the Bad, and What’s NextBroadcom Earnings Preview: AVGO Stock Near Record Highs Upcoming Earnings Bank of America (7/14/2025)America Movil (7/15/2025)Bank of New York Mellon (7/15/2025)BlackRock (7/15/2025)Citigroup (7/15/2025)JPMorgan Chase & Co. (7/15/2025)Progressive (7/15/2025)Charles Schwab (7/15/2025)UnitedHealth Group (7/15/2025)Wells Fargo & Company (7/15/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
